Status:
COMPLETED
In-Patient Study In Schizophrenic Patients
Lead Sponsor:
GlaxoSmithKline
Conditions:
Schizophrenia
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This study is a placebo-controlled study to assess the safety and tolerability of a novel antipsychotic medication, (773812) when given to schizophrenic patients for twenty-eight days. Assessments inc...
Eligibility Criteria
Inclusion
- Must have schizophrenia that has been stable for at least three months.
- Willing to discontinue current anti-psychotic medications (under supervision) prior to the study.
- Willing to live at the study center for a total of 38 days and then return for three follow-up visits.
Exclusion
- Taking medications for conditions other than schizophrenia.
- History of alcohol or drug abuse within six months of the study, and their alcohol consumption must meet moderate guidelines.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00197093
Start Date
September 1 2004
Last Update
May 18 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.